ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis
OSL:AZT - Euronext Oslo - NO0010014632 - Common Stock - Currency: NOK
Overall AZT gets a fundamental rating of 5 out of 10. We evaluated AZT against 73 industry peers in the Biotechnology industry. While AZT has a great health rating, its profitability is only average at the moment. AZT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZT was profitable.
In the past year AZT had a positive cash flow from operations.
AZT had positive earnings in each of the past 5 years.
AZT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AZT has a Return On Assets of 2.45%. This is in the better half of the industry: AZT outperforms 76.71% of its industry peers.
AZT has a better Return On Equity (2.61%) than 73.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.45% | ||
| ROE | 2.61% | ||
| ROIC | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 8.12%, AZT is in the better half of the industry, outperforming 79.45% of the companies in the same industry.
In the last couple of years the Profit Margin of AZT has declined.
Looking at the Gross Margin, with a value of 94.27%, AZT belongs to the top of the industry, outperforming 95.89% of the companies in the same industry.
AZT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 8.12% | ||
| GM | 94.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
2. Health
2.1 Basic Checks
AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZT has less shares outstanding
AZT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AZT has an improved debt to assets ratio.
2.2 Solvency
AZT has an Altman-Z score of 24.35. This indicates that AZT is financially healthy and has little risk of bankruptcy at the moment.
AZT has a Altman-Z score of 24.35. This is amongst the best in the industry. AZT outperforms 97.26% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that AZT is not too dependend on debt financing.
AZT has a better Debt to Equity ratio (0.01) than 82.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 24.35 |
ROIC/WACCN/A
WACC8.46%
2.3 Liquidity
AZT has a Current Ratio of 17.12. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
AZT has a better Current ratio (17.12) than 98.63% of its industry peers.
A Quick Ratio of 16.17 indicates that AZT has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.17, AZT belongs to the best of the industry, outperforming 98.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.12 | ||
| Quick Ratio | 16.17 |
3. Growth
3.1 Past
The earnings per share for AZT have decreased strongly by -93.94% in the last year.
Measured over the past years, AZT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -43.42% on average per year.
The Revenue for AZT has decreased by -12.26% in the past year. This is quite bad
AZT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.22% yearly.
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%
3.2 Future
AZT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.87% yearly.
The Revenue is expected to grow by 30.65% on average over the next years. This is a very strong growth
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 790.00 indicates a quite expensive valuation of AZT.
AZT's Price/Earnings ratio is a bit cheaper when compared to the industry. AZT is cheaper than 73.97% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.20. AZT is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 39.11 indicates a quite expensive valuation of AZT.
Based on the Price/Forward Earnings ratio, AZT is valued a bit cheaper than 78.08% of the companies in the same industry.
AZT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 790 | ||
| Fwd PE | 39.11 |
4.2 Price Multiples
AZT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AZT is cheaper than 71.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 125.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
AZT's earnings are expected to grow with 63.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)30.1
PEG (5Y)N/A
EPS Next 2Y69.87%
EPS Next 3Y63.87%
5. Dividend
5.1 Amount
AZT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:AZT (5/28/2025, 7:00:00 PM)
15.8
-0.4 (-2.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.46%
Inst Owner ChangeN/A
Ins Owners15.57%
Ins Owner ChangeN/A
Market Cap806.91M
Analysts76.67
Price Target19.38 (22.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)574.26%
Min EPS beat(2)-139.6%
Max EPS beat(2)1288.12%
EPS beat(4)1
Avg EPS beat(4)272.1%
Min EPS beat(4)-139.6%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)143.63%
EPS beat(12)4
Avg EPS beat(12)86.39%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.18%
Min Revenue beat(2)-18.99%
Max Revenue beat(2)2.64%
Revenue beat(4)1
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)2
Avg Revenue beat(8)-7.58%
Revenue beat(12)3
Avg Revenue beat(12)-4.81%
Revenue beat(16)6
Avg Revenue beat(16)-3.81%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-22.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 790 | ||
| Fwd PE | 39.11 | ||
| P/S | 7.73 | ||
| P/FCF | N/A | ||
| P/OCF | 486.38 | ||
| P/B | 2.49 | ||
| P/tB | 2.77 | ||
| EV/EBITDA | 125.77 |
EPS(TTM)0.02
EY0.13%
EPS(NY)0.4
Fwd EY2.56%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.03
OCFY0.21%
SpS2.04
BVpS6.35
TBVpS5.7
PEG (NY)30.1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.45% | ||
| ROE | 2.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 8.12% | ||
| GM | 94.27% | ||
| FCFM | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score4
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.85 | ||
| Cap/Depr | 144.69% | ||
| Cap/Sales | 9.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 32.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.12 | ||
| Quick Ratio | 16.17 | ||
| Altman-Z | 24.35 |
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
EBIT growth 1Y-109.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year342.86%
EBIT Next 3Y124.31%
EBIT Next 5YN/A
FCF growth 1Y-250.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.21%
OCF growth 3Y-71.92%
OCF growth 5Y-16%